Edoardo Pennesi, Erica Brivio, Anneke C J Ammerlaan, Yilin Jiang, Vincent H J Van der Velden, H Berna Beverloo, Barbara Sleight, Franco Locatelli, Benoit Brethon, Claudia Rossig, Gernot Engstler, Anna Nilsson, Benedicte Bruno, Arnaud Petit, Bella Bielorai, Carmelo Rizzari, Fanny Rialland, Alba Rubio-San-Simón, Francisco J Bautista Sirvent, Cristina Diaz-de-Heredia, Susana Rives, Christian M Zwaan
Inotuzumab Ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The Phase 1B of the ITCC-059 trial tested InO combined with chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Relapsed /refractory CD22+ BCP-ALL pediatric patients were enrolled. The primary objective was to establish the Recommended Phase 2 Dose (RP2D). Secondary objectives included preliminary efficacy and tolerability. InO was combined with 1.5 mg/m2 of vincristine (days 3, 10, 17, 24), 20 mg/m2 of dexamethasone (two 5-day blocks, then amended), and intrathecal therapy...
January 4, 2024: Haematologica